The Assessment of Serum Fibronectin Levels as a Potential Biomarker for the Severity of Drug-Sensitive Pulmonary Tuberculosis : A Pilot Study
BACKGROUND: Tuberculosis (TB) is a global health burden caused by Mycobacterium tuberculosis (Mtb) infection. Fibronectin (Fn) facilitates Mtb attachment to host cells. We studied the Fn levels in smear-positive TB patients to assess its correlation with disease severity based on sputum smears and chest X-rays.
METHODS: Newly detected consecutive sputum AFB-positive pulmonary TB patients (n = 78) and healthy control subjects (n = 11) were included. The mycobacterial load in the sputum smear was assessed by IUATLD classification, ranging from 0 to 3. The severity of pulmonary involvement was assessed radiologically in terms of both the number of zones involved (0-6) and as localized (up to 2 zones), moderate (3-4 zones), or extensive (5-6 zones). The serum human fibronectin levels were measured by using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Catalogue No: CK-bio-11486, Shanghai Coon Koon Biotech Co., Ltd., Shanghai, China).
RESULTS: The PTB patients showed lower Fn levels (102.4 ± 26.7) compared with the controls (108.8 ± 6.8), but they were not statistically significant. Higher AFB smear grades had lower Fn levels. The chest X-ray zones involved were inversely correlated with Fn levels. The Fn levels, adjusted for age and gender, decreased with increased mycobacterial load and the number of chest radiograph zones affected. A Fn level <109.39 g/mL predicted greater TB severity (sensitivity of 67.57% and specificity of 90.38%), while a level <99.32 pg/mL predicted severity based on the chest radiology (sensitivity of 84.21% and specificity of 100%).
CONCLUSIONS: The Fn levels are lower in tuberculosis patients and are negatively correlated with severity based on sputum mycobacterial load and chest radiographs. The Fn levels may serve as a potential biomarker for assessing TB severity, which could have implications for early diagnosis and treatment monitoring.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Diagnostics (Basel, Switzerland) - 14(2023), 1 vom: 25. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kulkarni, Shreedhar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Disease severity |
|---|
| Anmerkungen: |
Date Revised 01.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/diagnostics14010050 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366919458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366919458 | ||
| 003 | DE-627 | ||
| 005 | 20240201232127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics14010050 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM366919458 | ||
| 035 | |a (NLM)38201359 | ||
| 035 | |a (PII)50 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kulkarni, Shreedhar |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Assessment of Serum Fibronectin Levels as a Potential Biomarker for the Severity of Drug-Sensitive Pulmonary Tuberculosis |b A Pilot Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Tuberculosis (TB) is a global health burden caused by Mycobacterium tuberculosis (Mtb) infection. Fibronectin (Fn) facilitates Mtb attachment to host cells. We studied the Fn levels in smear-positive TB patients to assess its correlation with disease severity based on sputum smears and chest X-rays | ||
| 520 | |a METHODS: Newly detected consecutive sputum AFB-positive pulmonary TB patients (n = 78) and healthy control subjects (n = 11) were included. The mycobacterial load in the sputum smear was assessed by IUATLD classification, ranging from 0 to 3. The severity of pulmonary involvement was assessed radiologically in terms of both the number of zones involved (0-6) and as localized (up to 2 zones), moderate (3-4 zones), or extensive (5-6 zones). The serum human fibronectin levels were measured by using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Catalogue No: CK-bio-11486, Shanghai Coon Koon Biotech Co., Ltd., Shanghai, China) | ||
| 520 | |a RESULTS: The PTB patients showed lower Fn levels (102.4 ± 26.7) compared with the controls (108.8 ± 6.8), but they were not statistically significant. Higher AFB smear grades had lower Fn levels. The chest X-ray zones involved were inversely correlated with Fn levels. The Fn levels, adjusted for age and gender, decreased with increased mycobacterial load and the number of chest radiograph zones affected. A Fn level <109.39 g/mL predicted greater TB severity (sensitivity of 67.57% and specificity of 90.38%), while a level <99.32 pg/mL predicted severity based on the chest radiology (sensitivity of 84.21% and specificity of 100%) | ||
| 520 | |a CONCLUSIONS: The Fn levels are lower in tuberculosis patients and are negatively correlated with severity based on sputum mycobacterial load and chest radiographs. The Fn levels may serve as a potential biomarker for assessing TB severity, which could have implications for early diagnosis and treatment monitoring | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a disease severity | |
| 650 | 4 | |a fibronectin | |
| 650 | 4 | |a mycobacterial load | |
| 650 | 4 | |a sputum positive PTB | |
| 700 | 1 | |a Arunachala, Sumalatha |e verfasserin |4 aut | |
| 700 | 1 | |a Chaya, Sindaghatta Krishnarao |e verfasserin |4 aut | |
| 700 | 1 | |a ShankaraSetty, Rekha Vaddarahalli |e verfasserin |4 aut | |
| 700 | 1 | |a Karnik, Medha |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Nidhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ravindran, Sukanya |e verfasserin |4 aut | |
| 700 | 1 | |a Lokesh, Komarla Sundararaja |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Mikash |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleem Ullah, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Siddaiah, Jayaraj Biligere |e verfasserin |4 aut | |
| 700 | 1 | |a Mahesh, Padukudru Anand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 14(2023), 1 vom: 25. Dez. |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:25 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics14010050 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 25 |c 12 | ||